A continued rise in AMR could cause 10 million deaths per year across the globe by 2050 – more than currently die from cancer.^2​

The COVID-19 pandemic has reinforced a need to invest in diagnostics, infection prevention, surveillance, and stewardship now to help prevent future global health crises. We must take action to help protect our futures.^3-5​

It is estimated that 1.27 million deaths globally were caused by bacterial AMR in 2019. If no solution is found, this devastating impact is likely to worsen.⁶​

Antimicrobial medicines (antibiotics that target bacteria, antivirals that target viruses, and antifungals that target fungi) are among the most precious medical resources the world has ever known.^7​

Antibiotics have drastically changed modern medicine, extending the average human lifespan by 23 years.^8​

​

Similarities can be drawn between the COVID-19 pandemic and AMR pathogens, including the need for strong public health and preparedness measures.​

COVID-19 has threatened the progress made against resistant pathogens and impacted our ability to address AMR, making AMR an even more pressing threat.^9​

​

Only three classes of commonly prescribed antifungal drugs currently exist, so antifungal resistance can severely limit treatment options.^10​

​

No novel class of antibiotic has been discovered for almost 40 years. There are only 40 to 50 antibiotics in clinical development at present, while thousands of potential immuno-oncology therapies are currently being evaluated. The rate of innovation is insufficient to meet current and future needs.^11​